(VIANEWS) – MERCK AND CO INC (MRK.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MERCK AND CO INC (MRK.PA) | €101.40 | 2.61% | 29.69% |
| EQUASENS (EQS.PA) | €80.90 | 1.47% | 28.59% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MERCK AND CO INC (MRK.PA)
2.61% Forward Dividend Yield and 29.69% Return On Equity
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.82.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 21.04. Meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Moving Average
MERCK AND CO INC’s worth is under its 50-day moving average of €103.30 and higher than its 200-day moving average of €99.53.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 14, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 2.61%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MERCK AND CO INC’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
MERCK AND CO INC’s stock is valued at €101.40 at 07:30 EST, under its 52-week high of €110.00 and way above its 52-week low of €77.30.
More news about MERCK AND CO INC.
2. EQUASENS (EQS.PA)
1.47% Forward Dividend Yield and 28.59% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.1.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 26.1. Meaning, the purchaser of the share is investing €26.1 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 28.59%.
Yearly Top and Bottom Value
EQUASENS’s stock is valued at €80.90 at 07:30 EST, below its 52-week high of €86.60 and way higher than its 52-week low of €57.80.
More news about EQUASENS.
